Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
Crossref DOI link: https://doi.org/10.1007/s12185-016-2149-1
Published Online: 2016-12-20
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Suzuki, Kenshi
Handa, Hiroshi
Chou, Takaaki
Ishizawa, Kenichi
Takubo, Takatoshi
Kase, Yoichi
Funding for this research was provided by:
Takeda Pharmaceutical Company
License valid from 2016-12-20